Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory

Journal of Bioscience and Bioengineering

Volumn 102, Issue 6, 2006, Pages 485-496

  Kohchi, Chie ^a,b   Inagawa, Hiroyuki ^a,b,c   Nishizawa, Takashi ^a   Yamaguchi, Takatoshi ^d   Nagai, Shiro ^d   Soma, Gen Ichiro ^a,b  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c NATIONAL FISHERIES UNIVERSITY   (Japan)

^d Yaegaki Bio Indust Inc 681 H   (Japan)

Author keywords

innate immunity; macrophage network; prophylaxis; TLR4

Indexed keywords

INNATE IMMUNITY; LIPOPOLYSACCHARIDE (LPS); MACROPHAGE ACTIVATING SUBSTANCE; PROPHYLAXIS;

AQUACULTURE; BACTERIA; CELLS; DERMATITIS; HEALTH CARE; IMMUNOLOGY;

POLYSACCHARIDES;

IMMUNO POTENTIATOR FROM PANTOEA AGGLOMERANS 1; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

AGING; ALLERGY; AQUACULTURE; ARTICLE; ATOPIC DERMATITIS; CANCER; CHEMICAL STRUCTURE; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG USE; ENDOCYTOBIOSIS; GRAM NEGATIVE BACTERIUM; HEALTH CARE; HEALTH FOOD; HUMAN; HYPERLIPIDEMIA; IMMUNOPOTENTIATION; INFECTION; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLIC SYNDROME X; NONHUMAN; PANTOEA AGGLOMERANS; PROPHYLAXIS; SKIN CARE; STOMACH ULCER;

HUMANS; IMMUNITY, NATURAL; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MODELS, IMMUNOLOGICAL; PANTOEA; SIGNAL TRANSDUCTION;

ANIMALIA; NEGIBACTERIA; PANTOEA AGGLOMERANS; TRITICUM AESTIVUM;

EID: 33846497266     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1263/jbb.102.485     Document Type: Article

References (66)

1. Burnet F.M. Cellular immunology (1969), Melbourne University Press and Cambridge University Press
2. Burnet F.M. The clonal selection theory of acquired immunity (1959), Vanderbilt University Press, Nashiville
3. Soma G.-I., and Mizuno D.-I. Further development of the therapy with lipopolysaccharides of a small molecular size on various intractable diseases. In: Fiers W., and Buurman W.A. (Eds). Tumor necrosis factor: molecular and cellular biology and clinical relevance (1996), Karger, Basel 203-220
4. Tada T. The immune system as a supersystem. Annu. Rev. Immunol. 15 (1997) 1-13
5. Wiktor-Jedrzejczak W.W., Ahmed A., Szczylik C., and Skelly R.R. Hematological characterization of congenital osteopetrosis in op/op mouse. Possible mechanism for abnormal macrophage differentiation. J. Exp. Med. 156 (1982) 1516-1527
6. Kodama H., Nose M., Niida S., and Yamasaki A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J. Exp. Med. 173 (1991) 1291-1294
7. Pollard J.W., Hunt J.S., Wiktor-Jedrzejczak W., and Stanley E.R. A pregnancy defect in the osteopetrotic (op/op) mouse demonstrates the requirement for CSF-1 in female fertility. Dev. Biol. 148 (1991) 273-283
8. Michaelson M.D., Bieri P.L., Mehler M.F., Xu H., Arezzo J.C., Pollard J.W., and Kessler J.A. CSF-1 deficiency in mice results in abnormal brain development. Development 122 (1996) 2661-2672
9. Burke B., and Lewis C.E. The macrophage (2002), Oxford University Press, Oxford, New York
10. Kohchi C., Inagawa H., Hino M., Oda M., Nakata K., Yoshida A., Hori H., Terada H., Makino K., Takiguchi K., and Soma G.-I. Utilization of macrophages in anticancer therapy: the macrophage network theory. Anticancer Res. 24 (2004) 3311-3320
11. Nakamoto, T., Yoshimura, H., Honda, T., Nakata, K., Taniguchi, Y., Yoshida, A., Uenobe, M., Yoshioka, N., Yamaguchi, T., Inagawa, H., Kohchi, C., Nishizawa, T., and Soma, G-I.: Treatments for activating macrophages that reduces surgical stress and post operative mortalities from bacterial infections and tumor metastases. In Vivo (2007). (in press)
12. Meltzer M.S. Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation. J. Immunol. 127 (1981) 179-183
13. Lambert L.E., and Paulnock D.M. Modulation of macrophage function by gamma-irradiation. Acquisition of the primed cell intermediate stage of the macrophage tumoricidal activation pathway. J. Immunol. 139 (1987) 2834-2841
14. Suzuki M., Hisamatsu T., and Podolsky D.K. Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex. Infect. Immun. 71 (2003) 3503-3511
15. Wolfs T.G., Buurman W.A., van Schadewijk A., de Vries B., Daemen M.A., Hiemstra P.S., and van 't Veer C. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J. Immunol. 168 (2002) 1286-1293
16. Tanabe Y., Kitahara-Tanabe N., Mizuno D., and Soma G.-I. Enhanced production of tumour necrosis factor alpha (TNF-alpha) by its precursor on the cell surface of primed THP-1 cells. Cytokine 6 (1994) 337-348
17. Nishizawa T., Inagawa H., Oshima H., Okutomi T., Tsukioka D., Iguchi M., Soma G.-I., and Mizuno D. Homeostasis as regulated by activated macrophage. I. Lipopolysaccharide (LPS) from wheat flour: isolation, purification and some biological activities. Chem. Pharm. Bull. (Tokyo) 40 (1992) 479-483
18. Inagawa H., Nishizawa T., Tsukioka D., Suda T., Chiba Y., Okutomi T., Morikawa A., Soma G.-I., and Mizuno D. Homeostasis as regulated by activated macrophage. II. LPS of plant origin other than wheat flour and their concomitant bacteria. Chem. Pharm. Bull. (Tokyo) 40 (1992) 994-997
19. Kariluoto S., Aittamaa M., Korhola M., Salovaara H., Vahteristo L., and Piironen V. Effects of yeasts and bacteria on the levels of folates in rye sourdoughs. Int. J. Food Microbiol. 106 (2006) 137-143
20. Lindh E., Kjaeldgaard P., Frederiksen W., and Ursing J. Phenotypical properties of Enterobacter agglomerans (Pantoea agglomerans) from human, animal and plant sources. Apmis 99 (1991) 347-352
21. Vanneste J.L., Yu J., and Beer S.V. Role of antibiotic production by Erwinia herbicola Eh252 in biological control of Erwinia amylovora. J. Bacteriol. 174 (1992) 2785-2796
22. Nunes C., Usall J., Teixido N., Fons E., and Vinas I. Post-harvest biological control by Pantoea agglomerans (CPA-2) on Golden Delicious apples. J. Appl. Microbiol. 92 (2002) 247-255
23. Giddens S.R., Houliston G.J., and Mahanty H.K. The influence of antibiotic production and pre-emptive colonization on the population dynamics of Pantoea agglomerans (Erwinia herbicola) Eh1087 and Erwinia amylovora in planta. Environ. Microbiol. 5 (2003) 1016-1021
24. Raetz C.R. Biochemistry of endotoxins. Annu. Rev. Biochem. 59 (1990) 129-170
25. Bergey D.H., Krieg N.R., and Holt J.G. Bergey's manual of systematic bacteriology (1984), Williams & Wilkins, Baltimore
26. Okutomi T., Nishizawa T., Inagawa H., Takano T., Morikawa A., Soma G.-I., and Mizuno D. Homeostasis as regulated by activated macrophage. VII. Suppression of serum cholesterol level by LPSw (a lipopolysaccharide from wheat flour) in WHHL (Watanabe heritable hyperlipidemic) rabbit. Chem. Pharm. Bull. (Tokyo) 40 (1992) 1268-1270
27. Inagawa H., Saitoh F., Iguchi M., Nishizawa T., Okutomi T., Morikawa A., Soma G.-I., and Mizuno D. Homeostasis as regulated by activated macrophage. III. Protective effect of LPSw (lipopolysaccharide (LPS) of wheat flour) on gastric ulcer in mice as compared with those of other LPS from various sources. Chem. Pharm. Bull. (Tokyo) 40 (1992) 998-1000
28. Suzuki Y., Kobayashi A., Nishizawa T., Inagawa H., Morikawa A., Soma G.-I., and Mizuno D. Homeostasis as regulated by activated macrophage. VI. Protective effect of LPSw (a lipopolysaccharide from wheat flour) against acute infection by Toxoplasma gondii in mice. Chem. Pharm. Bull. (Tokyo) 40 (1992) 1266-1267
29. Iguchi M., Inagawa H., Nishizawa T., Okutomi T., Morikawa A., Soma G.I., and Mizuno D. Homeostasis as regulated by activated macrophage. V. Suppression of diabetes mellitus in non-obese diabetic mice by LPSw (a lipopolysaccharide from wheat flour). Chem. Pharm. Bull. (Tokyo) 40 (1992) 1004-1006
30. Del Prete G. The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int. Rev. Immunol. 16 (1998) 427-455
31. Mosmann T.R., and Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7 (1989) 145-173
32. Grewe M., Bruijnzeel-Koomen C.A., Schopf E., Thepen T., Langeveld-Wildschut A.G., Ruzicka T., and Krutmann J. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol. Today 19 (1998) 359-361
33. Desmedt M., Rottiers P., Dooms H., Fiers W., and Grooten J. Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses. J. Immunol. 160 (1998) 5300-5308
34. Inagawa H., Nishizawa T., Noguchi K., Minamimura M., Takagi K., Goto S., Soma G.-I., and Mizuno D. Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Anticancer Res. 17 (1997) 2153-2158
35. Goto S., Sakai S., Kera J., Suma Y., Soma G.I., and Takeuchi S. Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol. Immunother. 42 (1996) 255-261
36. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4 (2004) 71-78
37. Ohno S., Inagawa H., Dhar D.K., Fujii T., Ueda S., Tachibana M., Ohno Y., Suzuki N., Inoue M., Soma G.-I., and Nagasue N. Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the impact on FasL-mediated counterattack. Anticancer Res. 25 (2005) 463-470
38. Romani L. Immunity to fungal infections. Nat. Rev. Immunol. 4 (2004) 1-23
39. Takeda K., and Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17 (2005) 1-14
40. Akira S., and Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4 (2004) 499-511
41. Saitoh S., Akashi S., Yamada T., Tanimura N., Kobayashi M., Konno K., Matsumoto F., Fukase K., Kusumoto S., Nagai Y., Kusumoto Y., Kosugi A., and Miyake K. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int. Immunol. 16 (2004) 961-969
42. Itami T., Ohno N., Suzuki N., Doi K., Kondo M., Takahashi Y., Maeda M., Soma G.-I., Inagawa H., Honda T., and Yokomizo Y. Shrimp hemocytes can produce superoxide and nitric oxide. ITE Lett. 2 (2001) 70-74
43. Tsukioka D., Nishizawa T., Miyase T., Achiwa K., Suda T., Soma G.-I., and Mizuno D. Structural characterization of lipid A obtained from Pantoea agglomerans lipopolysaccharide. FEMS Microbiol. Lett. 149 (1997) 239-244
44. Jiang Z., Georgel P., Du X., Shamel L., Sovath S., Mudd S., Huber M., Kalis C., Keck S., Galanos C., Freudenberg M., and Beutler B. CD14 is required for MyD88-independent LPS signaling. Nat. Immunol. 6 (2005) 565-570
45. Suzuki J., Nishizawa T., Inagawa H., Okutomi T., Morikawa A., Soma G.-I., and Mizuno D. Homeostasis as regulated by activated macrophage. IX. Enhancement effect of LPSw (a lipopolysaccharide from wheat flour) on hen egg-laying and breaking strength of eggshell. Chem. Pharm. Bull. (Tokyo) 40 (1992) 1274-1276
46. Takahashi Y., Kondo M., Itami T., Honda T., Inagawa H., Nishizawa T., Soma G.-I., and Yokomizo Y. Enhancement of disease resistance against penaeid acute viraemia and induction of virus-inactivating activity in haemolymph of kuruma shrimp, Penaeus japonicus, by oral administration of Pantoea agglomerans lipopolysaccharide (LPS). Fish Shellfish Immunol. 10 (2000) 555-558
47. Cohen J. The immunopathogenesis of sepsis. Nature 420 (2002) 885-891
48. Braun-Fahrlander C., Riedler J., Herz U., Eder W., Waser M., Grize L., Maisch S., Carr D., Gerlach F., Bufe A., Lauener R.P., Schierl R., Renz H., Nowak D., and von Mutius E. Environmental exposure to endotoxin and its relation to asthma in school-age children. N. Engl. J. Med. 347 (2002) 869-877
49. Lauener R.P., Birchler T., Adamski J., Braun-Fahrlander C., Bufe A., Herz U., von Mutius E., Nowak D., Riedler J., Waser M., and Sennhauser F.H. Expression of CD14 and Toll-like receptor 2 in farmers' and non-farmers' children. Lancet 360 (2002) 465-466
50. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., and Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998) 2085-2088
51. Mandelboim O., Bar-Haim E., Vadai E., Fridkin M., and Eisenbach L. Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas. J. Immunol. 159 (1997) 6030-6036
52. Hoffman D.M., Gitlitz B.J., Belldegrun A., and Figlin R.A. Adoptive cellular therapy. Semin. Oncol. 27 (2000) 221-233
53. Haupt K., Roggendorf M., and Mann K. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp. Biol. Med. (Maywood) 227 (2002) 227-237
54. Conrad C., and Nestle F.O. Dendritic cell-based cancer therapy. Curr. Opin. Mol. Ther. 5 (2003) 405-412
55. Dodd M.J. BCG in cancer therapy: theoretical bases of immunotherapy. Am. J. Nurs. 79 (1979) 310-314
56. Sullivan B.P. BCG in cancer therapy: patient responses to BCG therapy for malignant melanoma. Am. J. Nurs. 79 (1979) 320-324
57. Aoyagi T., Ishizuka M., Takeuchi T., and Umezawa H. Enzyme inhibitors in relation to cancer therapy. Jpn. J. Antibiot. 30 suppl. (1977) 121-132
58. Talmadge J.E., and Herberman R.B. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep. 70 (1986) 171-182
59. Ogawa Y., Goodman G.B., Chaplin D.J., Grulkey W., and Lam G.K. Combination therapy of pions and SPG (Sonifilan, Schizophyllan), a biological response modifier for mouse tumor systems. Int. J. Radiat. Oncol. Biol. Phys. 18 (1990) 1415-1420
60. Jahrsdorfer B., and Weiner G.J. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr. Opin. Invest. Drugs 4 (2003) 686-690
61. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4 (2004) 249-258
62. Krieg A.M. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. 6 (2004) 88-95
63. Hussain I., and Kline J.N. CpG oligodeoxynucleotides: a novel therapeutic approach for atopic disorders. Curr. Drug Targets Inflamm. Allergy 2 (2003) 199-205
64. Hengge U.R., and Ruzicka T. Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol. Surg. 30 (2004) 1101-1112
65. Schon M.P., Wienrich B.G., Drewniok C., Bong A.B., Eberle J., Geilen C.C., Gollnick H., and Schon M. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J. Invest. Dermatol. 122 (2004) 1266-1276
66. Starnes C.O. Coley's toxins in perspective. Nature 357 (1992) 11-12